Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Monday . The company traded as high as $118.81 and last traded at $118.87, with a volume of 456889 shares trading hands. The stock had previously closed at $117.41.
Wall Street Analyst Weigh In
Several equities research analysts have weighed in on the company. Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, February 12th. Citigroup initiated coverage on Gilead Sciences in a research report on Thursday, November 14th. They set a "buy" rating and a $125.00 price objective for the company. Wells Fargo & Company lifted their target price on Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. JPMorgan Chase & Co. boosted their target price on Gilead Sciences from $105.00 to $115.00 and gave the stock an "overweight" rating in a research note on Wednesday, January 29th. Finally, Daiwa America upgraded shares of Gilead Sciences to a "hold" rating in a research note on Monday, November 18th. Eleven investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $104.52.
View Our Latest Analysis on Gilead Sciences
Gilead Sciences Stock Down 2.4 %
The firm has a market cap of $142.50 billion, a price-to-earnings ratio of 309.27, a PEG ratio of 0.71 and a beta of 0.21. The firm has a 50 day moving average of $100.12 and a 200 day moving average of $91.91. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. As a group, sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.
Gilead Sciences Increases Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be issued a dividend of $0.79 per share. The ex-dividend date is Friday, March 14th. This represents a $3.16 annualized dividend and a dividend yield of 2.76%. This is a positive change from Gilead Sciences's previous quarterly dividend of $0.77. Gilead Sciences's dividend payout ratio is currently 854.05%.
Insider Transactions at Gilead Sciences
In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the sale, the chief financial officer now owns 129,873 shares of the company's stock, valued at approximately $11,863,898.55. This trade represents a 1.89 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders have sold 293,356 shares of company stock valued at $29,166,240 in the last 90 days. 0.16% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the business. HHM Wealth Advisors LLC increased its holdings in Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 154 shares in the last quarter. YANKCOM Partnership purchased a new position in shares of Gilead Sciences during the fourth quarter valued at approximately $28,000. Decker Retirement Planning Inc. bought a new stake in Gilead Sciences during the fourth quarter worth $29,000. Crews Bank & Trust purchased a new stake in Gilead Sciences in the 4th quarter valued at $31,000. Finally, Stephens Consulting LLC lifted its stake in Gilead Sciences by 325.0% during the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock valued at $31,000 after acquiring an additional 260 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.
Gilead Sciences Company Profile
(
Get Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Featured Articles
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
